Eisai

An oral anti-angiogenic pill that matched sorafenib in liver cancer with higher response rates, and partners with pembrolizumab in kidney and endometrial cancer.

Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.

Alitretinoin gel is a vitamin A derivative applied directly to Kaposi sarcoma skin lesions in people with AIDS, approved in the United States in 1999 as the first topical treatment for the disease.

Pilocarpine tablets are approved to treat the dry mouth that follows head and neck radiotherapy; they help when some gland tissue is left, at the cost of sweating and other cholinergic side effects.

Denileukin diftitox (Lymphir) is an infusion that uses the interleukin-2 signal as a homing device to deliver a bacterial toxin into cutaneous T-cell lymphoma cells. It was withdrawn in 2014 and returned in an improved form in 2024.

A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.

Palonosetron (Aloxi) is a long-acting anti-sickness injection given once before chemotherapy; a single dose covers both the first day and the delayed nausea that follows.